LINC01235 regulate global histone modifications and enhances licensing factor accessibility
LINC01235 plays a crucial role in HER2-positive breast cancer by regulating global histone modifications (H3K27ac, H3K9ac, H3K36me3) and promoting H2A.Z expression in its regulatory regions. It enhances the accessibility of DNA licensing factors at their promoter regions, leading to increased DNA replication and chromosomal instability. These mechanisms contribute to clonal expansion and resistance to anti-HER2 therapies, highlighting LINC01235 as a potential therapeutic target. Overall design: Chromatin immunoprecipitation DNA-sequencing (ChlP-seg) for histone variants H2AZ as well as the histone modifications H3K27ac, H3K9ac and H3K36me3 in HCC1954 cells